A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection
<p>Abstract</p> <p>Background</p> <p>Over the last several decades, as a result of an evolution in manufacturing processes, a marked development has been made in the field of gonadotropins for ovarian stimulation. Initially, therapeutic gonadotropins were produced from...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
BMC,
2009-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_8dad2fa0657e411f9633c9b77fc97f3c | ||
042 | |a dc | ||
100 | 1 | 0 | |a Schneider Danielle T |e author |
700 | 1 | 0 | |a Verza Sidney |e author |
700 | 1 | 0 | |a Schertz Joan C |e author |
700 | 1 | 0 | |a Esteves Sandro C |e author |
700 | 1 | 0 | |a Zabaglia Silval FC |e author |
245 | 0 | 0 | |a A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection |
260 | |b BMC, |c 2009-10-01T00:00:00Z. | ||
500 | |a 10.1186/1477-7827-7-111 | ||
500 | |a 1477-7827 | ||
520 | |a <p>Abstract</p> <p>Background</p> <p>Over the last several decades, as a result of an evolution in manufacturing processes, a marked development has been made in the field of gonadotropins for ovarian stimulation. Initially, therapeutic gonadotropins were produced from a simple process of urine extraction and purification; now they are produced via a complex system involving recombinant technology, which yields gonadotropins with high levels of purity, quality, and consistency.</p> <p>Methods</p> <p>A retrospective analysis of 865 consecutive intracytoplasmic sperm injection (ICSI) cycles of controlled ovarian hyperstimulation (COH) compared the clinical efficacy of three gonadotropins (menotropin [hMG; n = 299], highly-purified hMG [HP-hMG; n = 330] and follitropin alfa [r-hFSH; n = 236]) for ovarian stimulation after pituitary down-regulation. The endpoints were live birth rates and total doses of gonadotropin per cycle and per pregnancy.</p> <p>Results</p> <p>Laboratory and clinical protocols remained unchanged over time, except for the type of gonadotropin used, which was introduced sequentially (hMG, then HP-hMG, and finally r-hFSH). Live birth rates were not significantly different for hMG (24.4%), HP-hMG (32.4%) and r-hFSH (30.1%; p = 0.09) groups. Total dose of gonadotropin per cycle was significantly higher in the hMG (2685 +/- 720 IU) and HP-hMG (2903 +/- 867 IU) groups compared with the r-hFSH-group (2268 +/- 747 IU; p < 0.001). Total dose of gonadotropin required to achieve clinical pregnancy was 15.7% and 11.0% higher for the hMG and HP-hMG groups, respectively, compared with the r-hFSH group, and for live births, the differences observed were 45.3% and 19.8%, respectively.</p> <p>Conclusion</p> <p>Although similar live birth rates were achieved, markedly lower doses of r-hFSH were required compared with hMG or HP-hMG.</p> | ||
546 | |a EN | ||
690 | |a Gynecology and obstetrics | ||
690 | |a RG1-991 | ||
690 | |a Reproduction | ||
690 | |a QH471-489 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Reproductive Biology and Endocrinology, Vol 7, Iss 1, p 111 (2009) | |
787 | 0 | |n http://www.rbej.com/content/7/1/111 | |
787 | 0 | |n https://doaj.org/toc/1477-7827 | |
856 | 4 | 1 | |u https://doaj.org/article/8dad2fa0657e411f9633c9b77fc97f3c |z Connect to this object online. |